news

CUPERTINO, Calif., April 18, 2005 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that effective April 14, 2005, the company has appointed Simon X. Benito to its Board of Directors to replace Albert L. Zesiger who is stepping down as a member of the Board of Directors. The appointment of Mr. Benito maintains […]

CUPERTINO, Calif., April 11 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today the expected departure of Thomas A. Schreck, Co-Founder and Chief Financial Officer on April 30, 2005, to pursue other interests in private ventures in the life sciences sector. Mr. Schreck will also be resigning as a director of the Company. Jian Li, DURECT’s

CUPERTINO, Calif., March 29, 2005 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference. The conference is taking place April 4-5th at The Millennium Broadway Hotel in New York City, New York. James E. Brown, DVM, President and Chief

CUPERTINO, Calif., March 14, 2005 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has signed an agreement with Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP), that will give Endo the exclusive license to develop and commercialize DURECT’s sufentanil-containing transdermal patch in the U.S. and

CUPERTINO, Calif., Feb 24, 2005 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Security Research Associates Spring Technology & Life Sciences Investor Conference at the Campton Place Hotel in San Francisco. Dr. James E. Brown, President and Chief Executive Officer, will be presenting at the conference on

CUPERTINO, Calif., Feb. 16 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals systems company, today announced the initiation of the Phase II program for DURECT’s TRANSDUR(TM)-based sufentanil patch. Based on the results of our Phase I trial for our TRANSDUR-Sufentanil patch that showed good safety, tolerability and drug release for up to 7

CUPERTINO, Calif., Feb 10, 2005 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today its financial results for the three months and year ended December 31, 2004. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) Our net loss for the three months ended December 31, 2004 was $7.0 million or 13 cents per share, compared to a net loss

CUPERTINO, Calif., Feb. 10 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals systems company, today announced the completion of dosing of the Phase I pharmacokinetic study for DURECT’s TRANSDUR(TM)-based sufentanil patch. The Company also announced the completion of dosing of the first cohort of the on-going Phase II clinical study for DURECT’s SABER(TM)-based

CUPERTINO, Calif., and RALEIGH, N.C., Jan 28, 2005 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical systems company, and Voyager Pharmaceutical Corporation, a privately held specialty pharmaceutical company focused on diseases of aging, announced today the completion of enrollment for the recently approved study for the DURIN(TM)-based leuprolide acetate product candidate

CUPERTINO, Calif., Jan. 25 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Paula Mendenhall has joined DURECT as Senior Vice President of Operations. Dr. Mendenhall has over 30 years of pharmaceutical experience covering areas such as research, manufacturing and pharmaceutical operations. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) “Dr. Mendenhall is a key addition to our management